Hyperbaric oxygen treatment in the management of necrotising soft-tissue infections: results from a Danish nationwide registry study.

BMJ Open

Department of Anaesthesia, Centre of Head and Orthopaedics, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Published: February 2023

AI Article Synopsis

  • The study evaluated the impact of hyperbaric oxygen (HBO) treatment on mortality in patients with necrotising soft-tissue infection (NSTI) while considering disease severity as a key factor.
  • Conducted in Denmark from January 2011 to June 2016, the research involved 671 NSTI patients and utilized advanced statistical methods to compare 30-day mortality between those who received HBO treatment and those who did not.
  • Results indicated that patients receiving HBO had significantly lower 30-day mortality rates (40% lower risk), suggesting HBO treatment may improve survival outcomes for NSTI patients despite differences in disease severity.

Article Abstract

Objectives: Application of hyperbaric oxygen (HBO) treatment in the multidisciplinary setting of necrotising soft-tissue infection (NSTI) is debated as a considerable number of studies are of low quality with marked prognostication bias due to inadequately addressing disease severity. The objective of this study was to associate HBO treatment with mortality in patients with NSTI including disease severity as a prognostic variable.

Design: Nationwide population-based register study.

Setting: Denmark.

Participants: Danish residents with NSTI patients between January 2011 and June 2016.

Primary And Secondary Outcome Measures: Thirty-day mortality was compared between patients receiving and patients not receiving HBO treatment using inverse probability of treatment weighting and propensity-score matching with predetermined variables (age, sex and weighted Charlson comorbidity score, presence of septic shock and Simplified Acute Physiology Score II (SAPS II)).

Results: A total of 671 NSTI patients were included with a median age of 63 (52-71), 61% male sex, 30% had septic shock and a median SAPS II of 46 (34-58). Patients who received HBO treatment (n=266) were younger and had lower SAPS II, but a larger fraction had septic shock compared with patients not receiving HBO treatment. Overall, all-cause 30-day mortality was 19% (95% CI 17% to 23%). The statistical models were in general acceptably balanced with covariates reaching <0.1 absolute standardised mean differences and patients receiving HBO treatment were associated with lower 30-day mortality (OR 0.40, 95% CI 0.30 to 0.53, p<0.001).

Conclusions: In analyses using inverse probability of treatment weighting and propensity score analysis, patients treated with HBO treatment were associated with improved 30-day survival.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950903PMC
http://dx.doi.org/10.1136/bmjopen-2022-066117DOI Listing

Publication Analysis

Top Keywords

hbo treatment
20
patients receiving
12
septic shock
12
hyperbaric oxygen
8
necrotising soft-tissue
8
disease severity
8
nsti patients
8
compared patients
8
receiving hbo
8
treatment
7

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!